Genetic Tech Spn Ads (GENE) 2.12 $GENE
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership
Marketwired - Wed Jun 22, 4:30AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
, a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann.
GENE: 2.12 (+0.02)
Genetic Technologies Limited (Nasdaq: GENE) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu May 05, 9:00AM CDT
What:
GENE: 2.12 (+0.02), NDAQ: 70.76 (-0.11)
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closing Bell on May 6th, 2016
Marketwired - Wed May 04, 4:30AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - May 4, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" , a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today that it will visit the Nasdaq MarketSite in New York City's Times Square and ring the Closing Bell on Friday, May 6th, 2016. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies, will be joined by international race car driver and BREVAGenplus spokesperson, Pippa Mann, to perform the honorary ringing of the bell. The Closing Bell will ring at 4.00pm ET and will be televised on major U.S. finance and business networks or can be viewed online at http://www.youtube.com/nasdaq/live and https://new.livestream.com/nasdaq/live.
GENE: 2.12 (+0.02)
4 Stocks Trading With Heavy Volume Today
ACCESSWIRE - Mon Dec 21, 9:45AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
GENE: 2.12 (+0.02), NTWK: 5.82 (-0.09), RWLK: 6.59 (+0.04), AVEO: 1.00 (-0.01)
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAGenplus(R)
Marketwired - Mon Dec 21, 4:30AM CST
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" announced today the publication of a new independent study in support of the BREVAGenplus(R) breast cancer risk assessment test for Caucasian women. The results were published online first in Cancer Epidemiology, Biomarkers & Prevention on December 16, 2015. The paper, entitled "Breast cancer risk prediction based on clinical models and 77 independent risk-associated SNPs in women aged under 50 years: Australian Breast Cancer Family Registry," can be accessed at: http://cebp.aacrjournals.org/content/early/20...8.abstract.
GENE: 2.12 (+0.02)
Biotech Sector Due Diligence Report Highlights 4 Emerging Companies - Broad Street Alerts
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Genetic Technologies Limited (NASDAQ: GENE), Can-Fite BioPharma Ltd. (NYSEMKT: CANF), KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), and Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are four tickers in the biotech space with varying degrees of fundamental strength. A recent slump in the sector has temporarily stymied the IPO pipeline and caused valuations to drop. Notably, through mid-October, the NASDAQ Biotech Index has declined 23% from its all-time high in July 2015. This has set up the sector quite nicely for a rebound and a surge as the decline was likely due to sentimental factors while fundamentals for most companies remained strong. Determining which company has strong fundamentals will prove to be profitable for the patient investor.
CANF: 2.10 (+0.03), GENE: 2.12 (+0.02), SRPT: 25.28 (+0.62)
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R)
Marketwired - Thu Aug 06, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" , is pleased to announce the issuance of US Patent Nos: 9,051,617 and 9,068,229 covering three of the core genetic markers referred to as single-nucleotide polymorphisms ("SNPs" in the Company's BREVAGenplus(R) risk assessment test. This patent family is assigned to Cambridge University, England and licensed exclusively to Genetic Technologies Limited. The patents comprise an important part of the commercialisation strategy for our first-in-class breast cancer risk assessment test.
GENE: 2.12 (+0.02)
Biotechnology Stocks on our Scanner -- Agenus, RXi Pharma, Nektar Therapeutics, Genetic Technologies, and Agios Pharma
PR Newswire - Fri Jul 31, 8:30AM CDT
Equity Research Institute has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Nektar Therapeutics (NASDAQ: NKTR), Genetic Technologies Ltd (NASDAQ: GENE) and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free research report on Agenus can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGEN. On Thursday, July 30, 2015, the NASDAQ Composite ended at 5,128.79, up 0.33%, the Dow Jones Industrial Average edged 0.03% lower, to finish the day at 17,745.98, and the S&P 500 closed flat at 2,108.63. During the session four out of nine sectors ended in positive. Register for your complimentary reports at the links given below.
GENE: 2.12 (+0.02), AGEN: 5.55 (+0.17), RXII: 2.35 (-0.02), AGIO: 45.23 (+1.37), NKTR: 17.29 (+1.19)
Genetic Technologies Announces Appointment of Chief Financial Officer
Marketwired - Mon Jun 15, 11:19PM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to announce the appointment of Mr. Brian Manuel as Chief Financial Officer, effective 15 June 2015.
GENE: 2.12 (+0.02)
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK
GlobeNewswire - Mon May 11, 10:36AM CDT
Carolynn Young, MD, Board-Certified Obstetrician and Gynecologist, announces that Rockville Gynecology is now offering BREVAGenplus(R), a state-of-the-art risk assessment test that helps physicians determine a patient's risk of developing sporadic, or non-hereditary, breast cancer.
GENE: 2.12 (+0.02)
The Health of Healthcare Companies: Complementary Research on Landmark Bancorp, Genetic Technologies, Novogen, CorMedix, and BioCryst
PR Newswire - Thu Apr 23, 6:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 1.49 (+0.03), GENE: 2.12 (+0.02), LARK: 25.75 (-0.08), BCRX: 3.62 (+0.16), NVGN: 1.86 (-0.02)
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R)
Marketwired - Mon Apr 20, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to announce that a further two (2) new breast health centres will begin to offer BREVAGenplus(R) to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company previously announced were set to adopt BREVAGenplus, of which all six (6) have in fact provided samples during the March 2015 quarter.
GENE: 2.12 (+0.02)
BUYINS.NET: GENE, KWEB, VGIT, Added To Naked Short Lists Today
M2 - Thu Apr 09, 10:47AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Genetic Technologies Ltd (NASDAQ:GENE), KWIKWEB.COM INC (NYSE:KWEB), Vanguard Intermediate Term Government Bond ETF (NASDAQ:VGIT). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
GENE: 2.12 (+0.02), KWEB: 35.09 (-0.31), VGIT: 67.14 (+0.22)
BUYINS.NET: GENE, CYTX, Removed From Naked Short Lists Today
M2 - Tue Mar 31, 4:25AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Genetic Technologies Ltd (NASDAQ:GENE), Cytori Therapeutics Inc (NASDAQ:CYTX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
GENE: 2.12 (+0.02), CYTX: 2.17 (+0.12)
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership
Marketwired - Wed Jun 22, 4:30AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
, a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann. GENE: 2.12 (+0.02)
Genetic Technologies Limited (Nasdaq: GENE) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu May 05, 9:00AM CDT
What:
GENE: 2.12 (+0.02), NDAQ: 70.76 (-0.11)
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closing Bell on May 6th, 2016
Marketwired - Wed May 04, 4:30AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - May 4, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
, a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today that it will visit the Nasdaq MarketSite in New York City's Times Square and ring the Closing Bell on Friday, May 6th, 2016. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies, will be joined by international race car driver and BREVAGenplus spokesperson, Pippa Mann, to perform the honorary ringing of the bell. The Closing Bell will ring at 4.00pm ET and will be televised on major U.S. finance and business networks or can be viewed online at http://www.youtube.com/nasdaq/live and https://new.livestream.com/nasdaq/live. GENE: 2.12 (+0.02)
4 Stocks Trading With Heavy Volume Today
ACCESSWIRE - Mon Dec 21, 9:45AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
GENE: 2.12 (+0.02), NTWK: 5.82 (-0.09), RWLK: 6.59 (+0.04), AVEO: 1.00 (-0.01)
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAGenplus(R)
Marketwired - Mon Dec 21, 4:30AM CST
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
announced today the publication of a new independent study in support of the BREVAGenplus(R) breast cancer risk assessment test for Caucasian women. The results were published online first in Cancer Epidemiology, Biomarkers & Prevention on December 16, 2015. The paper, entitled "Breast cancer risk prediction based on clinical models and 77 independent risk-associated SNPs in women aged under 50 years: Australian Breast Cancer Family Registry," can be accessed at: http://cebp.aacrjournals.org/content/early/20...8.abstract. GENE: 2.12 (+0.02)
Biotech Sector Due Diligence Report Highlights 4 Emerging Companies - Broad Street Alerts
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Genetic Technologies Limited (NASDAQ: GENE), Can-Fite BioPharma Ltd. (NYSEMKT: CANF), KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), and Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are four tickers in the biotech space with varying degrees of fundamental strength. A recent slump in the sector has temporarily stymied the IPO pipeline and caused valuations to drop. Notably, through mid-October, the NASDAQ Biotech Index has declined 23% from its all-time high in July 2015. This has set up the sector quite nicely for a rebound and a surge as the decline was likely due to sentimental factors while fundamentals for most companies remained strong. Determining which company has strong fundamentals will prove to be profitable for the patient investor.
CANF: 2.10 (+0.03), GENE: 2.12 (+0.02), SRPT: 25.28 (+0.62)
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R)
Marketwired - Thu Aug 06, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
, is pleased to announce the issuance of US Patent Nos: 9,051,617 and 9,068,229 covering three of the core genetic markers referred to as single-nucleotide polymorphisms ("SNPs" in the Company's BREVAGenplus(R) risk assessment test. This patent family is assigned to Cambridge University, England and licensed exclusively to Genetic Technologies Limited. The patents comprise an important part of the commercialisation strategy for our first-in-class breast cancer risk assessment test. GENE: 2.12 (+0.02)
Biotechnology Stocks on our Scanner -- Agenus, RXi Pharma, Nektar Therapeutics, Genetic Technologies, and Agios Pharma
PR Newswire - Fri Jul 31, 8:30AM CDT
Equity Research Institute has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Nektar Therapeutics (NASDAQ: NKTR), Genetic Technologies Ltd (NASDAQ: GENE) and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free research report on Agenus can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGEN. On Thursday, July 30, 2015, the NASDAQ Composite ended at 5,128.79, up 0.33%, the Dow Jones Industrial Average edged 0.03% lower, to finish the day at 17,745.98, and the S&P 500 closed flat at 2,108.63. During the session four out of nine sectors ended in positive. Register for your complimentary reports at the links given below.
GENE: 2.12 (+0.02), AGEN: 5.55 (+0.17), RXII: 2.35 (-0.02), AGIO: 45.23 (+1.37), NKTR: 17.29 (+1.19)
Genetic Technologies Announces Appointment of Chief Financial Officer
Marketwired - Mon Jun 15, 11:19PM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
is pleased to announce the appointment of Mr. Brian Manuel as Chief Financial Officer, effective 15 June 2015. GENE: 2.12 (+0.02)
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK
GlobeNewswire - Mon May 11, 10:36AM CDT
Carolynn Young, MD, Board-Certified Obstetrician and Gynecologist, announces that Rockville Gynecology is now offering BREVAGenplus(R), a state-of-the-art risk assessment test that helps physicians determine a patient's risk of developing sporadic, or non-hereditary, breast cancer.
GENE: 2.12 (+0.02)
The Health of Healthcare Companies: Complementary Research on Landmark Bancorp, Genetic Technologies, Novogen, CorMedix, and BioCryst
PR Newswire - Thu Apr 23, 6:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 1.49 (+0.03), GENE: 2.12 (+0.02), LARK: 25.75 (-0.08), BCRX: 3.62 (+0.16), NVGN: 1.86 (-0.02)
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R)
Marketwired - Mon Apr 20, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
is pleased to announce that a further two (2) new breast health centres will begin to offer BREVAGenplus(R) to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company previously announced were set to adopt BREVAGenplus, of which all six (6) have in fact provided samples during the March 2015 quarter. GENE: 2.12 (+0.02)
BUYINS.NET: GENE, KWEB, VGIT, Added To Naked Short Lists Today
M2 - Thu Apr 09, 10:47AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Genetic Technologies Ltd (NASDAQ:GENE), KWIKWEB.COM INC (NYSE:KWEB), Vanguard Intermediate Term Government Bond ETF (NASDAQ:VGIT). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
GENE: 2.12 (+0.02), KWEB: 35.09 (-0.31), VGIT: 67.14 (+0.22)
BUYINS.NET: GENE, CYTX, Removed From Naked Short Lists Today
M2 - Tue Mar 31, 4:25AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Genetic Technologies Ltd (NASDAQ:GENE), Cytori Therapeutics Inc (NASDAQ:CYTX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
GENE: 2.12 (+0.02), CYTX: 2.17 (+0.12)
